Two research groups find link between gene mutation and resistance to estrogen cancer therapy

November 4, 2013 by Bob Yirka, Medical Xpress report

(Medical Xpress)—Two teams of researchers, both made up of members from a wide variety of research institutions in the U.S. have independently come up with the same findings: a gene mutation in ESR1 (a gene that encodes estrogen receptors [ERs]) may be linked to resistance to estrogen therapies given to women to treat breast cancer. In their papers, both published in the journal Nature Genetics, the two teams describe their research and findings and how what they've found might help lead to new ways to treat breast cancer in the near future.

Breast cancer is the most common kind of cancer in women, and approximately seventy percent of such cases are sensitive to ER inhibition. One very common way to treat breast cancer is to use therapies that temporarily block ER activity or to prevent the creation of estrogen in the body at all. Unfortunately, over time, some types of breast cancers in some women become resistant to such treatment, especially if the cancer spreads to other parts of the body. In this latest effort both teams have been conducting research to find out why this is, and to try to find out if there is a way to prevent it from happening or to come up with different ways to apply the therapy to help prevent resistance from occurring.

Both teams enlisted the assistance of women who had a recurrence of breast cancer which had also metastasized. Tumor samples were taken and analyzed. Both teams found an increase in the incidence of mutations (14 of 80 cases in one study, 6 out of 11 in the other) in the part of the ESR1 gene responsible for causing ER to recognize estrogen. The mutations, the researchers note, allow the cancer to grow and spread in the absence of estrogen.

The did not prevent current therapies from working, the researchers noted, but instead made it so that more of it was needed to stop the tumors from growing or metastasizing—in some cases so much so that using such therapies became impractical.

Now that the ESR1 's connection to has been made, doctor's can screen patients for the mutation, alerting them to the need to switch to other therapies. It should also lead to new research to find out why the mutation occurs and to see if there is a way to prevent it from happening.

Explore further: Mutations linked to breast cancer treatment resistance

More information: ESR1 ligand-binding domain mutations in hormone-resistant breast cancer, Nature Genetics (2013) DOI: 10.1038/ng.2822
Activating ESR1 mutations in hormone-resistant metastatic breast cancer, Nature Genetics (2013) DOI: 10.1038/ng.2823

Related Stories

Mutations linked to breast cancer treatment resistance

November 3, 2013
Researchers at the University of Michigan Comprehensive Cancer Center have identified a type of mutation that develops after breast cancer patients take anti-estrogen therapies. The mutations explain one reason why patients ...

New models of drug-resistant breast cancer hint at better treatments

September 19, 2013
Breast cancer that spreads to other organs is extremely difficult to treat. Doctors can buy patients time, but a cure remains elusive. Now, researchers at Washington University School of Medicine in St. Louis have shown that ...

Studies show increasing evidence that androgen drives breast cancer

April 10, 2013
Estrogen and progesterone receptors, and the gene HER2 – these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors.

New risk gene discovery gives hope to early-onset breast cancer sufferers

October 24, 2013
A new breast cancer risk gene has been discovered which explains the early-onset breast cancer in some multiple-case breast cancer families.

Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors

June 15, 2013
A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute ...

Genes identify breast cancer risk and may aid prevention

March 19, 2013
A newly identified set of genes may predict which women are at high risk for getting breast cancer that is sensitive to estrogen and, therefore, would be helped by taking drugs to prevent it, reports a new Northwestern Medicine ...

Recommended for you

Researchers discover new anti-cancer protein

March 21, 2018
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from ...

Targeting telomeres to overcome therapy resistance in advanced melanoma

March 21, 2018
A study conducted at The Wistar Institute in collaboration with The University of Texas Southwestern Medical Center has demonstrated the efficacy of targeting aberrantly active telomerase to treat therapy-resistant melanoma. ...

Cancer comes back all jacked up on stem cells

March 19, 2018
After a biopsy or surgery, doctors often get a molecular snapshot of a patient's tumor. This snapshot is important - knowing the genetics that cause a cancer can help match a patient with a genetically-targeted treatment. ...

Researchers create a drug to extend the lives of men with prostate cancer

March 16, 2018
Fifteen years ago, Michael Jung was already an eminent scientist when his wife asked him a question that would change his career, and extend the lives of many men with a particularly lethal form of prostate cancer.

Machine-learning algorithm used to identify specific types of brain tumors

March 15, 2018
An international team of researchers has used methylation fingerprinting data as input to a machine-learning algorithm to identify different types of brain tumors. In their paper published in the journal Nature, the team ...

Higher doses of radiation don't improve survival in prostate cancer

March 15, 2018
A new study shows that higher doses of radiation do not improve survival for many patients with prostate cancer, compared with the standard radiation treatment. The analysis, which included 104 radiation therapy oncology ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.